Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 5/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2503926 | 1.00 | SLC7A5 (0.50) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL2512335 | 1.00 | SLC7A5 (0.50) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL12198928 | 0.91 | NOS1 (0.40) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL10448576 | 0.87 | CYP11B1 (0.42) | SLC7A5NOS1 | |
| SCHEMBL7300346 | 0.81 | SLC7A5 (0.47) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL11781896 | 0.79 | SLC7A5 (0.54) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL10397191 | 0.78 | CYP11B1 (0.55) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL8255653 | 0.78 | CYP11B1 (0.55) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL3684988 | 0.77 | SLC1A3 (0.49) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL22443734 | 0.76 | SLC1A3 (0.48) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245311-A1 | Histidine Derivatives | AKD GLOBAL, INC. | 2011-10-06 | — | — | US | claimed |
| WO-2010115130-A1 | HISTIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | AKD GLOBAL, INC. (US) | 2010-10-07 | — | — | WO | claimed |
| US-20110245311-A1 | Histidine Derivatives | AKD GLOBAL, INC. | 2011-10-06 | — | — | US | disclosed |
| WO-2010115130-A1 | HISTIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | AKD GLOBAL, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245311-A1 | Histidine Derivatives | HNMT, HAMP, PHPT1 | SLC7A5 78/4885ALPI 63/4885PKM 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.